Given the toxicity and limited therapeutic window of pan-PI3K inhibitors, attention has shifted toward isoform-specific agents, particularly those targeting the PI3Kα isoform, which is most frequently mutated in HR+/HER2– BC. This evidence concerns the gene ERBB2 and breast cancer.